CSIMarket


Exelixis Inc   (EXEL)
Other Ticker:  
 

Exelixis Inc

EXEL's Fundamental analysis








Looking into Exelixis Inc growth rates, revenue grew by 13.15 % in IV. Quarter 2023 from the same quarter a year ago. Ranking at No. 333

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -4.79 %

Exelixis Inc realized net income compared to net loss a year ago in IV. Quarter 2023

More on EXEL's Growth


Exelixis Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Exelixis Inc PEG ratio is at 2.43 Exelixis Inc realized cash outflow of $ -0.75per share in trailing twelve-month period.
Company
33.93
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.84.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.66.


More on EXEL's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 3,233,583
 Net Income/Employee (TTM) $ 822,060
 Receivable Turnover (TTM) 7.69
 Tangible Book Value (Per Share $) 6.88

Exelixis Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Exelixis Inc PEG ratio is at 2.43 Exelixis Inc realized cash outflow of $ -0.75per share in trailing twelve-month period.
Company
33.93
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.84.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.66.

Exelixis Inc Price to Book Ratio is at 3.1 lower than Indusry Avg. of 876.37. and higher than S&P 500 Avg. of -2103.47

More on EXEL's Valuation

  Market Capitalization (Millions $) 7,019
  Shares Outstanding (Millions) 320
  Employees 566
  Revenues (TTM) (Millions $) 1,830
  Net Income (TTM) (Millions $) 465
  Cash Flow (TTM) (Millions $) -240
  Capital Exp. (TTM) (Millions $) -40
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 3,233,583
  Net Income/Employee(TTM) $ 822,060
  Receivable Turnover Ratio (TTM) 7.69
  Tangible Book Value (Per Share $) 6.88

  Market Capitalization (Millions $) 7,019
  Shares Outstanding (Millions) 320
  Employees 566
  Revenues (TTM) (Millions $) 1,830
  Net Income (TTM) (Millions $) 465
  Cash Flow (TTM) (Millions $) -240
  Capital Exp. (TTM) (Millions $) -40


    EXEL's Profitability Comparisons
Exelixis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2023 to 17.05 %.

Exelixis Inc net profit margin of 39.31 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 8 in Healthcare sector and number 108 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 3.34
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 0.31
  Asset Turnover Ratio (TTM) 0.66
  Inventory Turnover Ratio (TTM) 2.88



Exelixis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in IV. Quarter 2023 to 17.05 %.

Exelixis Inc net profit margin of 39.31 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 8 in Healthcare sector and number 108 in S&P 500.

More on EXEL's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com